Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Breast International Group
European Organisation for Research and Treatment of Cancer - EORTC
NCIC Clinical Trials Group
ETOP IBCSG Partners Foundation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Non-metastatic primary invasive breast cancer overexpressing HER2 (determined by immunohistochemistry 3+ or positive fluorescence in situ hybridization test) that has been histologically confirmed, adequately excised, axillary node positive or negative, and tumor size at least T1c according to Tumor/Node/Metastasis (TNM) staging
Completion of at least 4 cycles of (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable
Known hormone receptor status
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55 percent (%)
You may not be if
Prior invasive breast carcinoma
Other malignancies except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
Clinical T4 tumors
Cumulative doxorubicin exposure greater than (\>) 360 milligrams per meter-squared (mg/m\^2) or epirubicin \>720 mg/m\^2 or any prior anthracyclines unrelated to the present breast cancer
Peripheral stem cell or bone marrow stem cell support
Prior mediastinal irradiation except for internal mammary node irradiation for the present breast cancer
Non-irradiated internal mammary nodes or supraclavicular lymph node involvement
Prior anti-HER2 therapy for any other reason or other prior biologic or immunotherapy for breast cancer
Concurrent anti-cancer treatment in another investigational trial
Serious cardiac or pulmonary conditions/illness, or any other conditions that could interfere with planned treatment
Poor hematologic, hepatic, or renal function
Pregnancy or lactation
Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures
